Research workbench
Amino terminal domain of enzyme I from escherichia COLI, NMR, restrained regularized mean structure
Analyse Amino terminal domain of enzyme I from escherichia COLI, NMR, restrained… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 2EZA
- Type
- protein
- Length
- 259 residues
- Chains
- 1
- Method
- solution nmr
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Phosphotransferase system, enzyme I
- EC
- 2.7.3.9
- UniProt
- P08839
- Pockets
- 3 · best druggability 0.60
Structure
solution nmr · 1 distinct chain · 54% helix, 12% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Phosphotransferase system, enzyme I (EC 2.7.3.9) | protein | 259 | 54% helix, 12% strand | P08839 |
Pockets
3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 358 | 0.60 | 0.77 | 41 | empty |
| 2 | 75 | 0.50 | 0.84 | 21 | empty |
| 3 | 68 | 0.35 | 0.77 | 18 | empty |
Compared structures
- 2EZA · Amino terminal domain of enzyme I from escherichia COLI, NMR, restrained regularized mean… · the same entry in another collection · chain A against A, TM-score 1.00
- P08839 · AlphaFold monomer V2.0 prediction for phosphoenolpyruvate-protein phosphotransferase… · a predicted model of the same protein · chain A against A, TM-score 0.87
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P08839
- Elsewhere: RCSB PDB 2EZA · PDBe 2EZA · UniProt P08839
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.